Dr. Joga Gobburu, a Drug Development and Regulatory Strategist, is a Professor at the University of Maryland. Before that, his extensive career includes significant roles at the US FDA from 1999 to 2011. His FDA tenure included overseeing thousands of INDs and over 250 licensing applications, forming the Division of Pharmacometrics. Joga's work has earned him numerous awards, including from the American Conference on Pharmacometrics and the American Society of Clinical Pharmacology. He has published over 120 papers and chapters.

Joan Korth-Bradley, PharmD, PhD, FCP, FAAPS, a Distinguished Scientist at Vivpro Corp. with over 30 years in drug development, specializing in clinical pharmacology. She has developed medicines in oncology, cardiology, anti-infectives, rheumatology, and rare diseases, working with small molecules, therapeutic proteins, and antibody-drug conjugates. Joan has published over 90 papers and serves on the editorial boards of key pharmacology journals. Her focus at Vivpro AI is using AI to address unmet medical needs, especially in underserved populations. Joan earned her PhD from the University of Texas at Austin and her PharmD from the University of Minnesota, Twin Cities.

Dr. Mary Ross Southworth served as Deputy Director for Safety in the Division of Cardiology and Nephrology at FDA’s CDER from 2008 to 2025. As the division’s principal drug safety expert, she guided regulatory and policy decisions across cardiovascular and renal therapies, overseeing safety throughout IND, NDA, and postmarketing stages. Dr. Southworth led initiatives on REMS, safety labeling, and postmarket surveillance, and contributed to programs like the Sentinel Initiative. Previously, she spent four years in the Office of Surveillance and Epidemiology. A clinical expert in cardiology, she served on the Heart Failure and Transplant Service at the University of Illinois at Chicago. She holds a BS Pharm from Virginia Commonwealth University, a PharmD from the University of Toledo, and completed a Cardiovascular Pharmacotherapeutics Residency at the University of Illinois at Chicago.

Dr. Pravin Jadhav, CEO of Vivpro Corp and expert in R&D Intelligence, has 19 years of experience in drug development and regulatory science, holding pivotal roles at the FDA, Merck, and Otsuka. He led significant projects involving over 100 NDAs and 150 INDs. Dr. Jadhav holds a PhD in Pharmaceutical Sciences from VCU and an MPH from Johns Hopkins University. His expertise ensures innovative, science-driven solutions for clinical and economic utility in pharmaceutical development.